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Posttranslational modifications occurring during the biosynthesis of G protein-coupled
receptors include glycosylation and palmitoylation at conserved cysteine residues
located in the carboxyl-terminus of the receptor. In a number of these receptors,
these modifications play an important role in receptor function and particularly, in
intracellular trafficking. In the present study, the three cysteine residues present in the
carboxyl-terminus of the human FSHR were replaced with glycine by site-directed
mutagenesis. Wild-type and mutant (Cys627/629/655Gly) FSHRs were then transiently
expressed in HEK-293 cells and analyzed for cell-surface plasma membrane expression,
agonist-stimulated signaling and internalization, and postendocytic processing in the
absence and presence of lysosome and/or proteasome inhibitors. Compared with the
wild-type FSHR, the triple mutant FSHR exhibited∼70% reduction in plasma membrane
expression as well as a profound attenuation in agonist-stimulated cAMP production and
ERK1/2 phosphorylation. Incubation of HEK-293 cells expressing the wild-type FSHR
with 2-bromopalmitate (palmitoylation inhibitor) for 6 h, decreased plasma membrane
expression of the receptor by ∼30%. The internalization kinetics and β-arrestin 1 and
2 recruitment were similar between the wild-type and triple mutant FSHR as disclosed
by assays performed in non-equilibrium binding conditions and by confocal microscopy.
Cells expressing the mutant FSHR recycled the internalized FSHR back to the plasma
membrane less efficiently than those expressing the wild-type FSHR, an effect that
was counteracted by proteasome but not by lysosome inhibition. These results indicate
that replacement of the cysteine residues present in the carboxyl-terminus of the
FSHR, impairs receptor trafficking from the endoplasmic reticulum/Golgi apparatus to
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the plasma membrane and its recycling from endosomes back to the cell surface
following agonist-induced internalization. Since in the FSHR these cysteine residues are
S-palmitoylated, the data presented emphasize on this posttranslational modification as
an important factor for both upward and downward trafficking of this receptor.
Keywords: follicle-stimulating hormone, follitropin, follicle-stimulating hormone receptor, palmitoylation,
internalization, recycling
INTRODUCTION
Follicle-stimulating hormone (FSH) or follitropin is a
glycoprotein hormone synthesized by the pituitary gland
that plays an essential role in the regulation of gonadal function.
Its cognate receptor (FSHR) belongs to the G protein-coupled
receptor (GPCR) superfamily and is mainly expressed in the
granulosa cells of the ovary and in the Sertoli cells of the
seminiferous tubule (Dias et al., 2002). Upon agonist binding,
the activated FSHR stimulates distinct intracellular signaling
cascades, mainly that involving the canonical Gαs/cAMP/PKA
pathway (Richards and Pangas, 2010; Ulloa-Aguirre et al.,
2011). As with other GPCRs, the FSHR undergoes agonist-
stimulated desensitization and internalization, a process that
involves phosphorylation by GPCR kinases and recruitment
of β-arrestin 1 and 2, which link the receptor-agonist complex
to components of the endocytic machinery (Krishnamurthy
et al., 2003a,b; Ulloa-Aguirre et al., 2011). Although most of the
FSH/FSHR complex accumulated in endosomes is subsequently
recycled back to the cell surface plasma membrane (PM),
a fraction of this complex is targeted for degradation by the
proteasomal/lysosomal machinery (Krishnamurthy et al., 2003a).
Posttranslational modifications occurring during the
biosynthesis of the FSHR include glycosylation and
palmitoylation at conserved cysteine residues located in
the carboxyl-terminus (Ctail) of the receptor (Davis et al.,
1995; Ulloa-Aguirre et al., 2013). Among several functions,
S-acylation with palmitic acid is required in many GPCRs,
including the glycoprotein hormone receptors [FSHR, lutropin
receptor (LHR), and thyrotropin receptor (TSHR)], for efficient
intracellular trafficking and for anchoring the carboxyl-terminal
domain of the receptor protein to the PM (Tanaka et al., 1998;
Munshi et al., 2001, 2005; Qanbar and Bouvier, 2003; Linder and
Deschenes, 2007; Uribe et al., 2008). Employing site-directed
mutagenesis, we previously documented that the human FSHR
is palmitoylated in its Ctail at two conserved cysteine residues
(Cys629 and Cys655) and one nonconserved residue (Cys627),
that is, at all cysteine residues regardless of their location in
this domain (Uribe et al., 2008). While palmitoylation at either
Cys627 or Cys655 is not essential for FSHR PM expression,
S-acylation at Cys629 is extremely important, as replacement
of this residue with alanine dramatically reduced expression of
the mature receptor by 40–70% (Uribe et al., 2008). In contrast
to the LHR, in which palmitoylation at conserved cysteine
residues is determinant for agonist-stimulated internalization
and postendocytic processing (Munshi et al., 2005), there is no
information on the role of this posttranslational modification on
the downward trafficking of the FSHR.
We here performed a series of experiments to examine the
intracellular traffic of a triple human FSHR mutant with all Ctail
cysteine residues mutated with glycine (FSHRC627/629/655G),
with special focus on the postendocytic processing of the
receptor. Gly instead of Ala was chosen to replace the Ctail
Cys residues of the receptor to allow a better comparison
of the downward trafficking parameters analyzed with those
previously reported for the Ctail Cys→Gly mutant of the
human LHR (Munshi et al., 2001, 2005). We found that the
functional behavior (PM expression, agonist-stimulated signaling
and internalization) and conformational changes of the triple
mutant FSHRC627/629/655G were similar to those exhibited by
the Cys→Ala mutant (Uribe et al., 2008). As a new information,
we demonstrated that replacement of Cys residues at the Ctail
of the FSHR, led to impaired recycling to the cell surface plasma
membrane after agonist-stimulated internalization, an effect that
was partially counteracted by inhibiting proteasome function.
These data indicate that palmitoylation does not influence
FSHR internalization but is important for its postendocytic
processing and recycling back to the PM after exposure to
agonist.
MATERIALS AND METHODS
Construction of the FSHRC627/629/655G
The plasmid designed for the expression of FSHRC627/629/655G
was obtained after three consecutive site-directed mutagenesis
reactions on the wild-type (WT) human FSHR cDNA (GeneBank
accession no. S59900) cloned into the mammalian expression
vector pSG-5 (Agilent Technologies, Santa Clara, CA, USA).
Site-directed mutagenesis was performed employing the
QuickChange II Site-Directed Mutagenesis kit (Agilent),
following the manufacturer instructions. The sequence of
mutagenic complementary oligonucleotides (Invitrogen,
Carlsbad, CA, USA) used for the replacement of cysteine for
glycine are shown inTable 1. Mutations at the target residues and
the fidelity of the remaining nucleotide sequence were verified
by automatic DNA sequencing. Large-scale plasmid DNAs for
transfection were prepared using an Endofree maxiprep kit
(Qiagen, Valencia, CA, USA).
Computational Modeling and Molecular
Dynamics Simulations of WT and Triple
Mutant FSHRs
The FSHR model was generated by means of the GPCR-I-
TASSER protocol (Zhang et al., 2015). Themodel with the highest
C-score was the initial structure in a molecular dynamics (MD)
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TABLE 1 | Sequence of mutagenic complementary oligonucleotides
employed to construct the triple Cys627/629/655Gly human FSHR mutant.
Residue Oligonucleotides
Cys627Gly Forward: 5′-CTG CTG AGC AAG GGT GGC TGC TAT G-3′
Reverse: 5′- C ATA GCA GCC ACC CTT GCT CAG CAG-3′
Cys 629Gly Forward: 5′-G AGC AAG GGT GGC GGC TAT GAA ATG C-3′
Reverse: 5′-G CAT TTC ATA GCC GCC ACC CTT GCT C-3′
Cys 655/Gly Forward: 5′-AGG AAT GGC CAC GGC TCT TCA GCT C-3′
Reverse: 5′-G AGC TGA ACA GCC GTG GCC ATT CCT-3′
set up. A preliminary validation of the FSHR model consisted of
a comparison against a second model using the sequence Leu241
to Asn678 to test consistency of the predictedmodel. Upon fitting
the backbone atoms from Leu348 to Gly628, which includes
the transmembrane helices and interhelical loops, a root mean
square deviation (RMSD) of 1.87 Å was calculated. All cysteines
were predicted in the same context in both structures. Another
preliminary validation was the transmembrane domains (TMD)
prediction along the FSHR sequence, using the physicochemical
and translocon hydropathy scales in the MPex server (Snider
et al., 2009). From the comparison of the predicted TMD
and the FSHR model, we concluded that the hydrophobicity
of the FSHR model was suited for a relaxation in a lipid
bilayer environment. Thus, the FSHR model was further refined
using MD simulation for the protein Asp300 to Asn678, which
contained a fragment of the amino-terminus, the transmembrane
helices, and the complete Ctail. The FSHR model was embedded
in a hydrated lipid bilayer of 1-stearoyl-2-docosahexaenoyl-sn-
glycero-3-phosphocholine (SDPC)molecules. In order to remove
any repulsive contact in the initial configuration, 3000 steps
of energy minimization using the conjugate gradient algorithm
were executed. After minimization, positional constraints were
defined on the heavy atoms of the protein. Starting from a
force constant of 25 kcal mol−1 Å−1, constraints were slowly
removed in 200 ps steps with force constants of 15, 10, 5, 3,
2, and 1 kcal mol−1 Å−1. Simulations were extended during 20
ns for the FSHR model without any constrain at 300K and 1
bar (NPT ensemble). The relaxed WT FSHR structure was also
used to generate two mutants by replacing Cys627, Cys629, and
Cys655 with glycine (Gly3 mutant) or alanine (Ala3 mutant).
In all the MD simulations, the FSHR model included only
the fragment Asp300 to Asn678, which contained an amino-
terminus shorter than native FSHR, the seven transmembrane
helices, and the complete Ctail. Trajectories of 20 to 24 ns
long were generated for each mutant. According to available
crystallographic data on GPCR (Murakami and Kouyama, 2008;
Murakami Kouyama and Kouyama, 2015), water molecules in
the interhelical region stabilize hydration of side chains and
form hydrogen bond chains, which may play a role for the
conformational changes toward the active state. Hence, water
molecules in the interhelical region were preserved from a
previous set up of squid rhodopsin in a SDPC lipid bilayer
(Jardon-Valadez et al., 2010).
Cell Culture and Transfection
Human embryonic kidney (HEK)-293 cells (ATTC, Manassas,
VA, USA) in high-glucose DMEM supplemented with 5%
fetal calf serum (FCS) and antibiotics were maintained in an
humidified atmosphere of 5% CO2 at 37◦C. Cells grown to 70–
80% confluency in 10 cm diameter dishes were replated on 60
mm diameter dishes and cultured for 24 h at 37◦C. Subconfluent
cells (∼750 × 103 cells/dish) were transfected with 4 µg WT,
mutant FSHR cDNAs or empty vector by liposome-mediated
endocytosis in OPTIMEM (Life Technologies, Grand Island,
NY). Transfected cells were then incubated for an additional 24
h before replating in 24-well-plates for subsequent experiments
or processed for immunoblotting. Co-transfections of WT and
mutant FSHR with cDNA constructs of β-arrestins [β-arrestin
1 and 2, or a dominant-negative form of β-arrestins (β-arrestin
319–418), Krupnick et al., 1997] were performed employing
3 µg of WT or mutant FSHR cDNA plus either 1 µg β-
arrestin 1, β-arrestin 2, β-arrestin 319–418, or empty vector. In
some experiments, cells expressing the WT FSHR were exposed
to 50 µM 2-bromopalmitate (an irreversible S-palmitoylation
inhibitor) (Sigma Aldrich, St. Louis, MO, USA) for 6 h, time
during which cell viability was not affected as assessed by
the yellow tetrazolium salt XTT assay (Roche Applied Science,
Mannheim, Germany), before the binding assay or preparation
of protein extracts for SDS-PAGE.
SDS-PAGE and Immunoblotting
SDS-PAGE (7.5%) and Western blotting of whole cell lysates
from cells expressing the WT or C627/629/655G cDNAs were
performed as described previously (Ulloa-Aguirre et al., 2013)
employing the primary anti-human FSHR antibody mAb106.105
(Lindau-Shepard et al., 2001) and the secondary anti-mouse
IgG horseradish peroxidase conjugate (Biosource International,
Armadillo, CA, USA). Signal was developed using the Pierce
ECL Western Blotting detection kit (Rockford, IL, USA).
Equal protein loading was verified in a reprobed membrane
with a 1:10000 anti-glyceraldehyde-3-phosphate dehidrogenase
(GAPDH) antibody (Sigma) and 1:15000 goat-anti-mouse IgG
conjugated with horseradish peroxidase (Biosource). In some
experiments, protein extracts (20–40 µg protein) were incubated
with 2000 units of Endo H (dissolved in 50 mm sodium citrate
pH 5.5) (New England Biolabs, Beverly, MA, USA) at 37◦C
for 16 h and the reaction was stopped by the addition of
Laemmli sample buffer before processing for 7.5% SDS-PAGE
and immunoblotting.
Receptor Binding Assay
Binding of 125I-FSH to the FSHR transiently expressed in HEK-
293 cells was assessed as previously described (Ulloa-Aguirre
et al., 2013). Cells cultured in 60 mM dishes were transfected
with the FSHR cDNAs and 24 h after transfection the cells were
replated in 24-well-plates. Forty-eight hours after transfection,
the medium was removed, replaced with fresh medium, and
allowed to continue incubation at 37◦C for 1 additional hour.
After the preincubation period, the medium was removed
and serum-free DMEM containing 20 ng/ml 125I-FSH (specific
activity ∼28 µCi/µg protein) was added to each well in the
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absence or presence of∼1 µg/ml recombinant FSH (to assess for
non-specific binding). Hormone was allowed to bind for 1 h at
37◦C and thereafter the plates were placed on ice and washed
twice with ice-cold PBS. Cell-surface 125I-FSH was eluted with
ice-cold 50mM glycine/100mM NaCl, pH 3.0 (elution buffer),
for 10 min on ice and the eluate was removed to a glass tube and
counted.
Measurement of cAMP Production
Forty-eight hours after transfection, the medium was removed
and the cells in 24-well-dishes were washed twice with DMEM-
5% FCS and then stimulated with increasing doses of human
recombinant FSH (Merck-Serono, Mexico D.F., Mexico) in the
presence of 0.125 mM 3-isobutyl-methyl-xanthine (Sigma). At
the end of the incubation period (18 h), themediumwas removed
and total (extracellular plus intracellular) cAMP accumulation
was measured by radioimmunoassay (Zambrano et al., 1996).
Internalization of the FSHR under
Nonequilibrium Binding Conditions
Internalization of the FSHR was performed as described
previously (Ulloa-Aguirre et al., 2013). Briefly, HEK-293
cells transfected with the WT or mutant FSHR cDNAs or
cotransfected with WT or mutant FSHR cDNAs and either β-
arrestin 1, β-arrestin 2, β-arrestin 319-418, or empty vector
were seeded into 24-well-plates pretreated with poly-D-lysine
(50µg/ml) (Sigma) at 1.5 × 105 cells/ml/well, and incubated
until subconfluency. After a 60min preincubation period in
serum-free DMEM, cells were exposed to 20 ng/ml 125I-FSH in
the presence or absence of 1 µg unlabeled recombinant FSH
for 0 to 90min or for 2 h at 37◦C. At each time point cells
were placed on ice, washed with PBS, and incubated on ice in
elution buffer for 20min to recover cell-surface 125I-FSH. After
the elute was removed for counting, cells were washed with
PBS and solubilized in 2N NaOH for 1 h at room temperature
to allow detection of cell-associated counts per minute. The
FSHR internalization rate is expressed as the internalized (cell-
associated)/surface 125I-FSH ratio.
Confocal Microscopy
Confocal microscopy was conducted to localize cell surface
and internalized FSHRs before and after FSH stimulation.
Transfected HEK-293 cells were cultured in Histogrip
(Invitrogen)-coated coverslips and exposed to 100 ng/ml FSH
for 2 h at 37◦C. Cells were then fixed with 2% paraformaldehyde
in PBS at 37◦C for 30min and bleached with 0.1M glycine for
5min. Cells were permeabilized with 0.05% Triton X-100 in PBS
for 10min at 4◦C and the slides were incubated in 1% bovine
serum albumin dissolved in PBS for 1 h at room temperature
to block nonspecific sites. Cells were then incubated with the
primary antibody Mab106.105 (1:200) for 12 h at 4◦C and
then with 1:200 FITC-conjugated anti-mouse IgG antibody
(Millipore, Temecula CA, USA) for 1 h at room temperature.
Slides were mounted in ProLong antifade reagent (Invitrogen)
and imaged on an Olympus FlowView FV10i confocal laser
scanning microscope (Olympus, Tokyo, Japan). The FV10-ASW
sofware (Olympus) was employed for imagen processing and
analysis. The FSHR fluorescence signal intensity across the
plane of the cells was analyzed using ImageJ 3D and Plot Profile
analysis (National Institutes of Health, Bethesda, MD, USA;
https://imagej.nih.gov/ij/), which displays the intensity of pixels
over the whole image surface or along a line as a 2-dimensional
graph. Lines were traced over the images obtained by confocal
microscopy to obtain the intensity values using the Plot Profile
plug-in. The values so obtained were plotted using the Prism 6
software (GraphPad Inc., CA, USA).
Recycling and Degradation of the
Internalized WT and Mutant FSHR
Postendocytic processing of the FSHR was assessed by the
pulse-chase procedure previously described (Ulloa-Aguirre et al.,
2013). In this assay, relative amounts of total recycled 125I-
FSH [trichloroacetic acid (TCA)-insoluble radioactivity in
the medium plus surface bound radioactivity] and degraded
125I-FSH (TCA-soluble radioactivity in the medium) are
determined at frequent incubation times during 4 h, after
allowing internalization of the receptor-ligand complex for
120min. At each time point, recycled 125I-FSH is an indirect
measurement of the amount of internalized receptor that was
recycled back to the plasma membrane, whereas the amount
of degraded 125I-FSH represents the fraction of the internalized
receptor that was targeted to lysosomes and/or proteasomes for
degradation. In some experiments, either 50 µM of MG132
(proteasome inhibitor), 100 nM of concanamycin A (lysosomal
inhibitor) (Sigma) or both were added to the incubation medium
after the initial 2 h incubation period.
FSH-Stimulated ERK1/2 Phosphorylation
Transfected cells were replated in 12-well-culture plates and
tested for FSH-stimulated ERK1/2 phosphorylation (Tranchant
et al., 2011). Briefly, after a 4 h preincubation period, 100 ng/ml
recombinant FSH were added to cells and incubated for 0–
120min. At the end of the incubation period, cells were lysed
in 2x Laemmly buffer and analyzed by Western blot. The
membranes were incubated overnight at 4◦C with anti-phospho-
ERK1/2 (1:3000; Cell Signaling Technology Inc., Beverly, MA,
USA) and then with secondary anti-mouse IgG horseradish
peroxidase conjugate (Biosource). Signal was developed as
described above. Equal protein loading was confirmed in a
membrane reprobed with primary polyclonal antibody against
total ERK2 (1:10,000; Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA).
Statistical Analysis
Differences between means from ≥2 groups were analyzed
employing either the unpaired Student’s t-test or one-way
analysis of variance (ANOVA) followed by post-hoc t-tests
with Bonferroni correction. To analyze differences between
the responses yielded by the internalization and recycling
experiments, the areas under the curves (AUC) were calculated
using GraphPad PRISM 4.0 (GraphPad Software, Inc., La Jolla,
CA, USA) and the corresponding means compared as described
above. Values and graphs shown are the means ± SD from three
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to five independent experiments. Probabilities of p < 0.05 were
considered statistically significant.
RESULTS
125I-FSH Binding, Western Blot Analysis,
and FSH-Stimulated cAMP Production
We first analyzed the PM expression and intracellular signaling
of the triple C627/629/655G FSHR mutant in order to test
the functional impact of replacing the Cys residues that are
palmitoylated in the WT FSHR with Gly. Compared to cells
transfected with the WT FSHR cDNA plasmid, 125I-FSH binding
toHEK-293 cells expressing themutant receptor was significantly
reduced at levels ∼30% from those observed for the WT FSHR
(Figure 1A). Western blot analysis of protein extracts from
cells transfected with the mutant FSHR cDNA confirmed the
limited PM expression levels of the mutant receptor as revealed
by a ∼70% reduction in intensity of the ∼80 KDa band that
represent the mature, PM-expressed, fully glycosylated FSHR
(Ulloa-Aguirre et al., 2013; Figure 1B). Intracellular signaling
mediated by the mutant FSHR also was attenuated as revealed
by a markedly reduced cAMP production (Figure 1C) and, to a
lesser extent, ERK1/2 phosporylation during the first 10 min of
exposure to the agonist (Figure 1D).
In addition to the functional studies described above, we also
applied computational modeling and MD simulation techniques
to investigate the impact of the Cys to Gly substitutions on the
conformational stability of the FSHR. For comparative purposes
we additionally generated 20 ns long trajectories for a WT FSHR
bearing non-palmitoylated Cys residues as well as for a mutant
receptor with all Ctail cysteine residues replaced with alanine.
The results of this in silico analysis are shown in Figures S1–
S3. As shown in these figures, the conformation of the 7-
transmembrane helices and the extra- and intracellular loops
of the three FSHRs modeled remained relatively stable across
FIGURE 1 | Plasma membrane expression (A,B) and FSH-stimulated cAMP production and ERK1/2 phosphorylation (C,D) of the WT and triple mutant.
FSHR. (A) Specific 125 I-labeled FSH binding to HEK-293 cells transiently expressing the WT or triple mutant FSHR. *p < 0.01. (B) Plasma membrane expression of
the triple mutant FSHR as disclosed by Western Blot analysis (relative to GAPDH expression, setting the WT FSHR at 1) (*p < 0.01). Inset, Relevant portion of an
authoradiogram from an immunoblot of the WT FSHR and the triple mutant FSHR. GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; (m): mature form of FSHR,
(i) immature form of FSHR. (C) Relative cAMP production of HEK-293 cells transiently expressing the WT FSHR or the triple mutant FSHR, exposed to increasing
doses of recombinant FSH during 18 h. *p < 0.01. (D) Kinetics of ERK phosphorylation (pERK) induced by exposure of HEK-293 transiently expressing the WT or
triple mutant FSHR to a fix dose (100 ng/ml) of recombinant FSH. In the densitometric analysis shown, the maximal WT FSHR-induced ERK phosphorylation was
arbitrarily chosen as 100%. Inset: Representative immunoblot for FSH-induced ERK phosphorylation. **p < 0.05.
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the 20 ns trajectory simulated, as disclosed by the evolution of
the corresponding root mean square deviation (RMSD) during
the simulation time (Figure S1). In all FSHRs, the amino acid
residues in positions 627 and 629 remained associated to the
lipid bilayer modeled. The analysis of the local conformational
changes along the protein chains during the last 4 ns of the
simulation revealed similar local fluctations for the triple FSHR
mutants (Cys to Gly and Cys to Ala mutants), including the
amino-terminal end of the Ctail, where residues 627 and 629 are
located, with larger fluctuations in the carboxyl-terminal end of
all receptors simulated (Figure S2, upper panel). Interesting, the
conformational fluctuations in the Ctail of the depalmitoylated
WT FSHR simulated were larger than those exhibited by the
FSHR mutants, emphasizing on the importance of S-acylation
at Cys residues on the conformational stability of this particular
domain (Figure S2, lower panels). Monitoring of the secondary
structure elements (α-helices and β-strands) throughout the
simulation trajectory confirmed the larger fluctuations of the
carboxyl-terminal end of all simulated receptors and the relative
stability of the α-helices, including the amino-terminal end of the
Ctail (Figure S3).
In ensemble, these data indicate that substitution of the
Cys residues at the FSHR Ctail with glycine impaired FSHR
receptor expression and intracellular signaling as previously
observed for the alanine-mutated receptor (Uribe et al., 2008),
albeit with slight differences in the level of PM expression and
agonist-stimulated intracellular signaling despite the similarities
in magnitude of both conformational changes and regional
fluctuations between the two receptor mutants.
Digestion with Endoglycosidase H of the
WT and Triple Mutant FSHR
To corroborate that, in fact, the 80 KDa band observed in the
immunoblotting analysis of the C627/629/655G FSHR mutant
described above corresponded to the fraction of mature FSHR
that reached the PM, we performed Endo-H digestion of both
the triple mutant and the WT FSHR. As shown in Figures 2A,B,
incubation of protein extracts from cells transiently expressing
the WT and mutant FSHR with Endo-H, resulted in a gel
shift of the ∼75 KDa band representing immature, incompletely
processed FSHR down to bands with lower molecular weights,
which correspond to more immature forms (Ulloa-Aguirre et al.,
2013). In the case of the FSHRC627/629/655G, this shift was
more clearly evident when gels were loaded with twice the
amount of protein and overexposed (Figure 2B). These results
indicated that replacement of cysteine residues at the Ctail of the
FSHR did not influence on receptor glycosylation as the intensity
of the PM-expressed, mature FSHR 80 KDa form in both theWT
and triple mutant receptor remained unchanged after Endo-H
exposure.
WT FSHR PM Expression in the Presence
of 2-Bromopalmitate
Since in other GPCRs S-palmitoylation plays in important
role in intracellular trafficking of the receptor from the
endoplasmic reticulum-Golgi compartment to the PM (Qanbar
and Bouvier, 2003), we assessed PM expression of the WT
FSHR after incubation with the S-palmitoylation inhibitor 2-
bromopalmitate (Davda et al., 2013) for 6 h. Exposure of cells
expressing the WT FSHR to the irreversible palmitoylation
inhibitor for 6 h, resulted in decreased PM expression of the
receptor as disclosed by immunoblotting (∼20% reduction in
intensity of the 80 KDa band compared with the corresponding
band from control cells; Figure 2C) and receptor binding (∼30%
decrease in specific 125I-FSH binding; Figure 2D). These data
indicated that reduction or abolition of palmitoylation by either
incubating in the presence of 2-bromopalmitate or mutating the
cysteine residues present in the Ctail decreased PM expression
of the FSHR, which secondarily could lead to reduced signaling
response to agonist exposure.
Internalization and β-Arrestin 1 and 2
Recruitment
Next we examined the effects of replacing the cysteine residues
of the FSHR Ctail on agonist-stimulated downward trafficking
of the PM-expressed receptor. Given that agonist-induced
desensitization is followed by internalization of the agonist-
bound receptor and that in both processes β-arrestins play
an important role, we first studied the internalization kinetics
of the mutant FSHR and its regulation by β-arrestin 1 and
2. As illustrated in Figure 3A, the internalization kinetics of
the triple FSHR mutant [expressed as the relationship between
the amount (cpms) of internalized and surface-bound 125I-
FSH at time 90min] was comparable to that shown by the
unmodified receptor. Confocal microscopy of cells transiently
expressing the FSHR before and 2 h after FSH exposure
confirmed that the mutant FSHR internalized with similar
efficiency to its WT counterpart (Figure 3B and Figure S4). In
basal conditions, fluorescence could be predominantly identified
at the cell periphery, whereas 2 h after agonist exposure
there was a strong increase in fluorescence inside the cells
(Figure S4B, lower panel). Figure 3C shows the internalization
of 125I-FSH in cells expressing the WT and mutant FSHR
after 90min exposure to FSH in cells overexpressing β-
arrestin-1 and -2 or β-arrestin 319–418. Over-expression of
either β-arrestin 1 or 2, led to a significant increase in
the internalization rate of both the WT and mutant FSHRs,
whereas overexpression of the dominant-negative form of β-
arrestins reduced internalization of both receptors by nearly
50%. The magnitude of changes in FSHR internalization under
these conditions was similar for the WT and the mutant
FSHR. These results indicated that the replacement of all Ctail
cysteine residues with glycine, preventing palmitoylation of
the FSHR, neither significantly altered endogenous β-arrestin
recruitment nor agonist-stimulated internalization. Further,
although themagnitude of FSH-stimulated ERK phosphorylation
in cells transfected with the triple mutant FSHR was modest
(due to low PM expression), the pattern of FSH-stimulated
ERK1/2 activation, which depends on both Gαs/PKA- and
β-arrestins 1 and 2-dependent pathways (Kara et al., 2006;
Shenoy et al., 2006), was virtually indistinguishable between
cells expressing the WT or mutant FSHR (Figure 1D). Mock-
transfected HEK-293 cells did not show any FSH-induced pERK
(not shown).
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FIGURE 2 | Digestion of the FSHR with Endo H and plasma membrane expression upon exposure of HEK-293 cells expressing the WT FSHR to the
palmitoylation inhibitor 2-bromopalmytate. (A) Representative Western blot analysis of the WT and triple mutant FSHR before (control) and after treatment of
protein extracts with Endo-H. A reduction in the intensity of the 75 KDa band but not in the 80 KDa band was observed as a result of Endo-H digestion; in (B) gels
were uploaded with twice the amount of protein extracts from cells expressing the triple mutant FSHR, and anti-FSHR antibody-probed membranes were then
overexposed to the radiographic film. (C) Representative immunoblot and densitometric analysis of the WT FSHR from cells treated with 50 µM 2-bromopalmitate or
vehicle alone (DMSO, control). A reduction in the intensity of the band corresponding to the FSHR was found as disclosed by densitometric analysis (right panel). (m):
mature form of FSHR, (i) immature form of FSHR. (D) The plasma membrane expression of the WT FSHR was also reduced as a result of the brief (6 h) exposure to
the palmitoylation inhibitor, as revealed by receptor binding studies.*p < 0.05 vs. control.
Degradation and Recycling of the
FSH/FSHR
The fate of FSHRC627/629/655G following agonist-provoked
internalization was studied employing the pulse-chase procedure
described in Material and Methods. Figure 4 shows that cells
transiently expressing the cysteine-replaced Ctail FSHR recycled
internalized 125I-FSH back to the plasma membrane less
efficiently than those expressing the WT receptor (Figures 4A,B;
AUC of total 125I-FSH recycled/240min in cells transfected with
FSHRC627/629/655G: 88 ± 2 vs. 121 ± 4 in cells expressing
the WT receptor; p < 0.05). Accordingly, more secreted but
degraded, TCA-soluble 125I-FSH (which reflects the fraction of
the internalized receptor that was targeted to lysosomes and/or
proteasomes) was recovered from themedium of cells transfected
with the FSHRC627/629/655G (AUC of TCA-soluble 125I-FSH
fraction/240min: 140 ± 4) than from those expressing the WT
receptor (125I-FSH/240min: 125 ± 4; p < 0.05) (Figure 4C),
whereas the opposite was observed for the TCA-precipitable
125I-FSH fraction (Figure 4C, inset). Finally, the amount of cell
associated 125I-FSH/240min was significantly higher in cells
transfected with the triple Cys FSHR mutant (AUC/240min:
173 ± 2) than in those transfected with the WT receptor
(AUC/240min: 146 ± 2; p < 0.05; Figure 4D). Nevertheless,
at the end of the incubation period (4 h), the fraction of 125I-
FSH that remained cell associated was the same for both WT-
and FSHRC627/629/655G-transfected cells; this result correlated
with the data depicted in Figures 4A–C showing higher amounts
of WT receptor recycling back to the PM and, conversely, higher
amounts of degraded 125I-FSH and secreted as TCA-soluble 125I
by cells transfected with the triple mutant receptor.
To confirm that FSHRC627/629/655G recycled less to the PM
than the WT receptor after agonist-stimulated internalization as
a consequence of increased proteasomal/lysosomal degradation,
further recycling experiments were performed in the absence
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FIGURE 3 | FSH-stimulated internalization of 125I-FSH measured under non-equilibrium binding conditions in the absence (A,B) or presence of
overexpressed β-arrestins (C). (A) Internalized (cell associated)/surface 125 I-FSH ratio in cells transiently expressing either the WT or the triple mutant FSHR as a
function of time. The internalization kinetics were similar between the two FSHRs. (B) Internalization of WT and mutant FSHR before (basal) and after 2-h exposure to
recombinant FSH as assessed by confocal microscopy. The intracellular fluorescence increased in both HEK-293 cells expressing the WT and the triple mutant FSHR
after exposure to agonist for 2 h. This was more evident in the case of the WT FSHR due to its much higher expression compared to that exhibited by the triple
mutant receptor (See Figures 1A,B). (C) Agonist-stimulated internalization of the 125 I-FSH/FSHR complex in cells transiently co-transfected with either the WT or the
mutant FSHR and β-arrestin 1, β-arrestin 2 or dominant-negative arresting (319–418). Under these conditions the internalization of both receptors were virtually the
same. Different letters among bars indicate statistical differences (<0.05) within each FSHR. See supplementary information (Figure S4) for details on the fluorescence
analysis of the images shown in (B).
or presence of inhibitors of lysosome and/or proteasome
degradation. As shown in Figures 5 and 6, addition of the
lysosomal inhibitor concanamycin A failed to increase the
amount of recycled FSHR in cells expressing either the WT
or the mutant FSHR (Figures 5A,B). It should be noticed that
although exposure to the lysosome inhibitor provoked a marked
decrease in the amount of degraded 125I-FSH, the fraction
of cell associated hormone was higher than in unexposed
conditions, particularly at 4 h (Figures 5C,D). By contrast,
exposure to the proteasome inhibitor MG132 for 2 and 4 h,
resulted in a significant increase in the fraction of recycled
WT and mutant FSHR and a parallel decrease in the secreted
125I-FSH TCA soluble fraction. Further, the increase in recycled
FSHR (WT and mutant) in response to proteasome inhibitor
correlated with a significant increment in specific 125I-FSH
binding after 4 h of incubation (Figure 6). For both FSHRs,
specific 125I-FSH binding in cells exposed to MG132 was twice
as much as that exhibited by cells unexposed to the inhibitor,
whereas in cells exposed to concanamycin A alone there were
no changes in specific agonist binding. Nevertheless, the more
than two-fold increase in agonist binding after exposure to
MG132, might reflect not only inhibition of proteasomal
degradation after internalization but also during the upward
trafficking of the receptor from the endoplasmic reticulum/Golgi
compartments to the PM. These results indicate that abrogation
of FSHR palmitoylation by replacing all Ctail cysteine
residues, does not affect internalization of the FSH/FSHR
complex, but favors sorting of the complex to the degradation
pathway.
DISCUSSION
Given their particular physicochemical properties, cysteine
residues in the carboxyl-terminus of GPCRs are susceptible to
several post-translational modifications, including formation of
disulfide bonds and lipid modifications (Zhou et al., 2014).
Disulfide bonds in the cytosolic compartment are quite unstable
due to the reducing environment, whereas S-acylation with
palmitic acid is a well-conserved and prevalent posttranslational
modification among members of the GPCR superfamily (Qanbar
and Bouvier, 2003). Besides facilitating association of the
Ctail with the plasma membrane, promoting formation of
a fourth cytoplasmic loop, several studies have documented
other functional roles for palmitoylation in GPCRs, which will
vary depending on the particular receptor, and that include
modulation of receptor conformation, coupling to effectors,
regulation of intracellular trafficking and PM localization,
desensitization, and postendocytic processing (Bouvier et al.,
1995; Qanbar and Bouvier, 2003; Resh, 2006; Linder and
Deschenes, 2007). In the case of glycoprotein hormone
receptors, mutation of Cys699 with alanine, a potential site of
palmitoylation in the TSHR, has been shown to slow upward
intracellular trafficking (Tanaka et al., 1998), whereas in the LHR
replacement of two contiguous cysteine residues (621 and 622)
with glycine did not affect PM expression of the receptor but
led to a marked increase in ligand-stimulated internalization and
decreased recycling back to the PM.
Herein, we mutated all cysteine residues present in the Ctail
of the human FSHR. We have previously shown that all three
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FIGURE 4 | Kinetics of recycling back to the plasma membrane of the WT and triple mutant FSHR after agonist-provoked internalization. (A) Cell
surface 125 I-FSH bound to the recycled FSHR throughout the second, 4 h incubation (see Materials and Methods). The relative amount of cell surface
125 I-FSH/mutant FSHR complex was less compared to that shown by the WT receptor (see Results Section). (B) Total 125 I-FSH/FSHR complex recycled back to the
plasma membrane (cell surface 125 I-FSH plus TCA precipitable 125 I-FSH), following exposure of HEK-293 cells transiently expressing the WT or mutant FSHR to
agonist. Total recycled FSH/mutant FSHR complex was decreased compared to the FSH/WT FSHR complex (see Results Section). (C) TCA-soluble (degraded)
radioactivity recovered from the culture medium throughout the second, 4 h incubation. Less soluble radioactivity was recovered at time 4 h in media from cells
transfected with the mutant receptor; meanwhile, more TCA precipitable (undegraded) 125 I-FSH was recovered in the media from cells expressing the WT FSHR
(inset). (D) Cell-associated 125 I-FSH recovered during the second incubation.
cysteine residues present in this domain are palmitoylated (Uribe
et al., 2008). In fact, alanine substitution of Ctail cysteine residues
led to complete abrogation of palmitoylation and decreased
specific 125I-FSH binding, cell surface PM expression, and
agonist-stimulated intracellular signaling. Here we found that
in cells expressing the FSHRC627/629/655G, PM expression of
the mature form of the receptor was drastically reduced, thus
confirming our previous findings (Uribe et al., 2008). Further, we
observed that a brief (6 h) exposure to 2-bromopalmitate, was
accompanied by a ∼20% decrease in the amount of the mature
form of FSHR protein and concomitantly in ∼30% 125I-FSH
binding. These data suggest that abrogation of palmitoylation
of the FSHR by removing all Ctail cysteine residues, limits the
traffic of the receptor to the PM, as documented for other
GPCRs (Gao et al., 1999; Petaja-Repo et al., 2006; Adams et al.,
2011). Nevertheless, our data do not allow to unambiguously
identify whether the limited cell surface PM expression of the
mutant FSHR was primarily due to the lack of palmitoylation
per se or to changes in the conformation of the Ctail domain
as replaced residues in positions 627 and 629 are near the
F(X)6LL sequence, which is closely involved in the transport of
several GPCRs (including the FSHR) to the PM (Duvernay et al.,
2004; Timossi et al., 2004). Further, MD simulation of mutant
FSHRs with individual alanine replacements in Ctail cysteine
residues revealed that mutants involving position 629 yielded
the most unstable structures, with the triple mutant structure
resulting in a highly unstable conformer (Uribe et al., 2008), more
susceptible to rapid degradation. In this vein, it was interesting
to find that the conformational changes exhibited by the Ctail
of the FSHR Gly3 mutant were similar to those observed in
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FIGURE 5 | Recycling of the WT and triple mutant FSHR after agonist-provoked internalization (time zero), in the presence and absence of
concanamycin A (lysosomal inhibitor), MG132 (proteasome inhibitor) or both. Total recycled FSH/FSHR complex increased upon exposure to MG132 but not
concanamycin A (A,B). Meanwhile, the fraction of TCA soluble (degraded) 125 I-FSH in media from cells expressing the WT (C) or mutant FSHR (D) decreased in the
presence of either MG132, concanamycin A or both (see Results). Different letters among bars indicate statistical differences (<0.05) within each time (0, 2, or 4 h).
the Ala3 FSHR and that exposure to the proteasome inhibitor
MG132 led to a more than two-fold increase in FSH binding
to both WT and mutant receptor, which may be an indication
of the impact of proteasomal degradation on both upward and
downward trafficking of the FSHR. In fact, it has been shown
that palmitoylation-deficient mutants of some GPCRs, such as
the human A1 adenosine receptor, are more prone to rapid
proteolytic degradation (Gao et al., 1999). According to this
information, we may conclude that the significant reduction
in PM expression of Ctail Cys mutant FSHRs (Uribe et al.,
2008 and present study) in basal conditions may be due to
several factors, including abrogation of palmitoylation, receptor
misfolding, and increased proteasomal degradation, all of which
may limit trafficking of the receptor from the endoplasmic
reticulum and/or Golgi compartments to the plasma membrane.
We found that FSH-stimulated phosphorylation of ERK1/2
followed a similar kinetics when mediated by either the WT
or FSHRC627/629/655G, that is, a rapid and transient increase
in pERK peaking 5 min after agonist exposure, which mainly
depends on Gαs activation, followed by an increased level
above basal during the ensuing 30–60 min, which is G protein-
independent but β-arrestin-dependent (Kara et al., 2006). The
finding of a stronger effect of the mutations on FSH-stimulated
cAMP production than in ERK1/2 phosphorylation, might reflect
the contribution of endogenous β-arrestins to activation of
this kinase. In fact, we found that the endogenous β-arrestin
recruitment by the triple mutant FSHR was virtually identical
to that shown by the WT receptor. These findings suggest
that mutation of all cysteine residues present in the Ctail
of the FSHR, although adversely affected the cAMP response
to agonist, did not parallely alter with the same intensity
the efficacy to elicit ERK phosphorylation via the β-arrestin-
dependent pathway, despite its low PM expression levels. A
similar dissociation in response to agonist has also been reported
for the misfolded A189V FSHR mutant, which associates with
intracellular retention of the FSHR and severely impaired cAMP
production (Tranchant et al., 2011). Whether this difference in
response to agonist is due to biased signaling of the mutant
FSHR or to conditional bias secondary to alterations in the
stoichiometry of receptor-interacting partners (Landomiel et al.,
2014) remains to be further investigated. In this regard, studies
in other GPCRs, such as the endothelin A receptor documented
that depalmitoylation was associated to biased signaling, with
a selective loss in its ability to couple to Ca2+ mobilization
without affecting the Gs/cAMP pathway (Horstmeyer et al.,
1996).
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FIGURE 6 | Specific 125I-FSH binding in HEK-293 cells expressing the
WT or the triple mutant FSHR at the end of the second, 4 h incubation
period of the recycling experiments, in the absence (control) or
presence of MG132, concanamycin A (Con A), or both. *p < 0.05 vs.
control for the same FSHR.
In the present study, we provided new information on the
role of Ctail cysteine residues in downward trafficking of the
FSHR, particularly on the kinetics of its postendocytic processing
after agonist-stimulated internalization. Most investigators agree
in that palmitoylation influence the downward trafficking of
transmembrane proteins, including internalization, endocytosis,
recycling, and degradation (Chini and Parenti, 2009). In the case
of the LHR, it has been shown that prevention of palmitoylation
by mutating the Ctail Cys residues to glycine, leads to both
increase in agonist-stimulated internalization and reduction in
the efficiency of recycling of the internalized receptor back to
the PM (Munshi et al., 2005). Since palmitoylation-deficient
GPCRs, including the LHR, may be hyperphosphorylated
(Munshi et al., 2001), it has been speculated that decreased
recycling of the depalmitoylated LHR could be due to resistance
to endosomal dephosphorylation of the hyperphosphorylated
receptor (Munshi et al., 2005). Here, we found that recycling
of the internalized triple mutant FSHR back to the PM was
considerably reduced. The observation that the internalization
rate and its dependency to β-arrestins was comparable for the
FSHRC627/629/655G and WT receptors, suggesting that the
mutant FSHR was not hyperphosphorylated, makes resistance to
dephosphorylation a less plausible explanation for the increased
degradation of the FSHR mutant. Rather, it appears that the
decreased recycling of FSHRC627/629/655G was due to failure of
the altered Ctail to correctly interact with the recycling endosome
machinery or to properly interact with proteins associated with
recycling to the PM [e.g., the GPCR interacting protein Na+-
H+ exchange regulatory factor or NHERF1, which promotes
recycling of the β2-adrenergic receptor and the κ-opioid receptor
(Cao et al., 1999; Li et al., 2002)], thereby favoring sorting of
the mutant receptor to the lysosomal/proteasomal degradation
pathway. Since palmitoylation of Cys655 appears to be involved
in the internalization of the FSHR (Uribe et al., 2008), it is
also possible that absence of palmitoylation in this location may
promote decreased recycling to the PM given that this particular
cysteine residue is located near a downstream, short amino acid
sequence determinant for postendocytic processing of the FSHR
(Krishnamurthy et al., 2003b). Whatever the mechanism(s) by
which the absence of S-palmitoylation increase degradation
of the ligand/receptor complex, the present findings unveil
additional structural components (i.e., S-palmitoyable cysteine
residues) involved in efficient recycling of the internalized FSHR
back to the PM.
Similarly to findings in the β2-adrenergic receptor and the
µ- and δ-opioid receptor (Chaturvedi et al., 2001; Shenoy et al.,
2001), our experiments showed that the increased degradation
of the triple mutant FSHR was counteracted by proteasomal
inhibition, thus suggesting that the ubiquitination-proteosomal
degradation pathway is primarily involved in FSHR degradation
after agonist-stimulated internalization. In fact, it has been
shown that the WT FSHR is ubiquitinated and that proteasomal
inhibitors increase cell surface residency of this receptor (Cohen
et al., 2003), as it was observed in the present study. This finding
contrasts with the results from incubations in the presence of
concanamycin A, in which exposure to this lysosomal inhibitor
led to increased accumulation of internalized hormone due to
a decrease in hormone degradation but without modifying the
total recycled receptor or hormone/receptor complex to the cell
surface. This accumulation of internalized hormone might be
due to perturbation in the flux through the proteasomes in the
presence of the lysosomal disruptors, as it has been observed
in other ubiquitinated proteins (Korolchuk et al., 2009; Qiao
and Zhang, 2009). Due to the pulse-chase strategy employed to
analyze the postendocytic processing of the internalized 125I-
FSH/FSHR complex, it is not possible to discern whether the
125I-FSH remaining in the cell associated fraction (presumably
in endosomal compartments) in the presence of concanamycin
A corresponds to 125I-FSH complexed with or dissociated
from the FSHR, which afterward recycled back to the PM.
Nevertheless, the finding that specific 125I-FSH binding in the
presence or absence of concanamycin A was virtually the same,
indicates that the radioactivity remaining in the cell associated
fractions rather corresponded to FSH complexed with the
FSHR.
It was interesting to find that the combination of
concanamycin AwithMG132 further increased the recycled 125I-
FSH fraction and concomitantly decreased that corresponding
to the degraded fraction. This finding suggests that lysosomal
degradation still may have a place in the postendocytic processing
of the FSHR.
In summary, the results presented herein, demonstrate
that replacement of cysteine residues with glycine in the Ctail
of the FSHR markedly decreased both upward trafficking of
the receptor to the PM as well as its recycling back to the
PM following agonist-stimulated internalization, without
modifying the internalization kinetics of the FSH/FSHR
complex. These alterations in FSHR trafficking provoked
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by deprivation of cysteine residues at the Ctail, may be
due to the absence of S-acylation or to the conformational
alterations in this particular domain provoked by the
mutations. These findings contrast with those reported for
the structurally related LHR, in which replacement of Ctail
cysteine residues (preventing palmitoylation of the receptor),
did not significantly modify the upward trafficking of the
receptor but markedly altered the internalization kinetics
and postendocytic processing of the cysteine-lacking receptor
(Munshi et al., 2001, 2005). Collateraly, the data also suggest
that the ubiquitin/proteasome pathway operates upstream of
trafficking to lysosomes to regulate the postendocytic processing
of the human FSHR.
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